期刊
BIOMOLECULES
卷 12, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/biom12091229
关键词
endometrial cancer; metabolomics; oncological screening; ensemble machine learning
资金
- POR Campania FESR [B61G18000470007]
Endometrial cancer is the most common gynecological neoplasm in high-income countries, but no validated screening tests are currently available. This study validated a metabolomics signature as an effective screening test for symptomatic women, demonstrating that serum metabolome can serve as a cost-effective, non-invasive, and accurate EC screening test.
Endometrial cancer (EC) is the most common gynecological neoplasm in high-income countries. Five-year survival rates are related to stage at diagnosis, but currently, no validated screening tests are available in clinical practice. The metabolome offers an unprecedented overview of the molecules underlying EC. In this study, we aimed to validate a metabolomics signature as a screening test for EC on a large study population of symptomatic women. Serum samples collected from women scheduled for gynecological surgery (n = 691) were separated into training (n = 90), test (n = 38), and validation (n = 563) sets. The training set was used to train seven classification models. The best classification performance during the training phase was the PLS-DA model (96% accuracy). The subsequent screening test was based on an ensemble machine learning algorithm that summed all the voting results of the seven classification models, statistically weighted by each models' classification accuracy and confidence. The efficiency and accuracy of these models were evaluated using serum samples taken from 871 women who underwent endometrial biopsies. The EC serum metabolomes were characterized by lower levels of serine, glutamic acid, phenylalanine, and glyceraldehyde 3-phosphate. Our results illustrate that the serum metabolome can be an inexpensive, non-invasive, and accurate EC screening test.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据